Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2

Conditions

Sarcoma, Myeloid 2Leukemia, Myeloid, Acute 2Sarcoma, Clear Cell 1

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × devimistat × Sarcoma × Clear all
NCT02484391 2024-09-19

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Wake Forest University Health Sciences

Phase 1 Completed
48 enrolled 13 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05854966 2024-09-19

CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Wake Forest University Health Sciences

Phase 2 Withdrawn
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡